Liquidia Dirección
Dirección controles de criterios 4/4
El CEO de Liquidia es Roger Jeffs , nombrado en Jan 2022, tiene una permanencia de 4.58 años. compensación anual total es $7.71M, compuesta por 10.7% salario y 89.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 2.06% de las acciones de la empresa, por valor de $126.32M. La antigüedad media del equipo directivo y de la junta directiva es de 3.1 años y 6.8 años, respectivamente.
Información clave
Roger Jeffs
Chief Executive Officer (CEO)
US$7.7m
Compensación total
| Porcentaje del salario del CEO | 10.68% |
| Permanencia del CEO | 4.6yrs |
| Participación del CEO | 2.1% |
| Permanencia media de la dirección | 3.1yrs |
| Promedio de permanencia en la Junta Directiva | 6.8yrs |
Actualizaciones recientes de la dirección
Recent updates
LQDA: Patent Rulings Will Shape Future Pulmonary Hypertension Earnings Power
Analysts have raised the fair value estimate for Liquidia stock from $60 to $90, citing higher Street price targets driven by strong Yutrepia uptake, growing market share, and additional long term optionality from L606, alongside ongoing legal and earnings considerations. Analyst Commentary Recent Street research on Liquidia points to a mixed but generally constructive tone.Liquidia: YUTREPIA's Launch Opens Upside If Growth Remains And Margins Follow
Summary YUTREPIA's commercial launch continues to scale, with Q2 product sales of $170.4 million, up 31% sequentially. Q2 largely resolved the margin concern: product gross margin remained about 93.7% despite fully costed inventory, while operating margin reached roughly 49.8%. The key debate has shifted from profitability to growth. Liquidia now needs about $210 million of quarterly revenue in Q3 and Q4 to reach the current $725 million FY2026 consensus. Read the full article on Seeking Alpha
LQDA: Future Patent Decisions Seen Driving Upside As Sentiment Turns More Positive
Analysts have lifted their fair value estimate for Liquidia stock from $102.99 to $130.00, reflecting updated assumptions on litigation outcomes around YUTREPIA and views that the drug could play a central role in treating PAH and PH-ILD if current legal and intellectual property questions are resolved in the company's favor. Analyst Commentary Recent Street research on Liquidia highlights a mix of optimism and caution that centers on litigation milestones, the commercial trajectory of YUTREPIA, and how these factors could influence the stock's valuation over time.LQDA: Pending Patent Outcomes Will Drive Future Earnings Upside Or Downside
Analysts lifted their fair value estimate for Liquidia to $60.00 from $16.99, citing higher Street price targets, stronger conviction in Yutrepia's potential positioning in PAH and PH-ILD, and updated assumptions around earnings power and legal outcomes. These changes are reflected in revised discount rate, margin, and future P/E inputs.LQDA: Legal Outcomes Around Key Patent Will Drive Future Upside
Analysts have lifted their implied fair value estimate for Liquidia from about $67.00 to roughly $103.00, citing updated models that reflect stronger expectations for Yutrepia, higher peak sales assumptions up to $2.2b, and legal outcomes that they view as better framed after recent court decisions. Some now prefer to wait for more clarity on key patent litigation before assuming further upside.
LQDA: Legal Outcomes And Earnings Power Will Shape The Next Phase
Analysts have lifted the updated fair value estimate for Liquidia to $72.38 from $44.00, as higher assumed profit margins, a lower future P/E multiple, and evolving views on legal and earnings risk reshape their price target frameworks. Analyst Commentary Recent Street research on Liquidia highlights a mix of enthusiasm around potential earnings power and caution around legal outcomes, which together shape how analysts think about valuation and execution risk.Liquidia (LQDA) Stock Could Be 63.2% Overvalued After PHA 2026 YUTREPIA Update
Liquidia (LQDA) is back in focus after the company outlined four new poster presentations at the PHA 2026 International PH Conference, spotlighting fresh YUTREPIA data and broader pulmonary hypertension care insights. See our latest analysis for Liquidia. The PHA 2026 conference update comes at a time when Liquidia’s momentum has been strong, with a 30 day share price return of 26.12% and a 5 year total shareholder return of 2,737.94%. Together, these figures point to sentiment that has...Upgrade: Analysts Just Made A Captivating Increase To Their Liquidia Corporation (NASDAQ:LQDA) Forecasts
Shareholders in Liquidia Corporation ( NASDAQ:LQDA ) may be thrilled to learn that the analysts have just delivered a...Liquidia Corporation (NASDAQ:LQDA) Looks Just Right With A 30% Price Jump
Liquidia Corporation ( NASDAQ:LQDA ) shares have had a really impressive month, gaining 30% after a shaky period...Liquidia Corporation's Long-Running Saga Is Coming To An End
Summary Today, we are circling back on Liquidia Corporation, as its long-running litigation battle with United Therapeutics is finally coming to a positive end. This means we will likely see the full commercial launch of its primary candidate, YUTREPIA before the end of the second market. YUTREPIA is targeting a large potential market and could garner significant market share. An updated analysis around Liquidia Corporation follows in the paragraphs below. Read the full article on Seeking AlphaAnálisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$139m |
| Mar 31 2026 | n/a | n/a | US$22m |
| Dec 31 2025 | US$8m | US$824k | -US$69m |
| Sep 30 2025 | n/a | n/a | -US$124m |
| Jun 30 2025 | n/a | n/a | -US$149m |
| Mar 31 2025 | n/a | n/a | -US$137m |
| Dec 31 2024 | US$7m | US$800k | -US$128m |
| Sep 30 2024 | n/a | n/a | -US$117m |
| Jun 30 2024 | n/a | n/a | -US$102m |
| Mar 31 2024 | n/a | n/a | -US$97m |
| Dec 31 2023 | US$5m | US$689k | -US$79m |
| Sep 30 2023 | n/a | n/a | -US$58m |
| Jun 30 2023 | n/a | n/a | -US$51m |
| Mar 31 2023 | n/a | n/a | -US$37m |
| Dec 31 2022 | US$11m | US$325k | -US$41m |
| Sep 30 2022 | n/a | n/a | -US$46m |
| Jun 30 2022 | n/a | n/a | -US$44m |
| Mar 31 2022 | n/a | n/a | -US$41m |
| Dec 31 2021 | US$93k | n/a | -US$35m |
| Sep 30 2021 | n/a | n/a | -US$39m |
| Jun 30 2021 | n/a | n/a | -US$47m |
| Mar 31 2021 | n/a | n/a | -US$54m |
| Dec 31 2020 | US$89k | n/a | -US$60m |
Compensación vs. Mercado: La compensación total ($USD7.71M) de Roger está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD8.35M).
Compensación vs. Ingresos: La compensación de Roger ha sido consistente con los resultados de la empresa en el último año.
CEO
Roger Jeffs (64 yo)
Dr. Roger A. Jeffs, Ph D., serves as Director at Liquidia Corporation (formerly known as Liquidia Technologies, Inc.) since November 2020 and serves as its Chief Executive Officer from January 3, 2022. He...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 4.6yrs | US$7.71m | 2.06% $ 126.3m | |
| COO & CFO | 5.8yrs | US$4.16m | 0.39% $ 23.7m | |
| General Counsel & Corporate Secretary | 5.4yrs | US$3.67m | 0.52% $ 32.2m | |
| Chief Commercial Officer | 5.8yrs | US$2.68m | 0.086% $ 5.3m | |
| Chief Medical Officer | 4.1yrs | US$2.92m | 0.037% $ 2.3m | |
| Chief Accounting Officer | 1.1yrs | sin datos | 0.074% $ 4.5m | |
| Senior VP | 1.1yrs | sin datos | sin datos | |
| Senior Vice President of Marketing | 1.6yrs | sin datos | sin datos | |
| Senior Vice President of Sales | 1.6yrs | sin datos | sin datos | |
| Chief Human Resources Officer | 3.2yrs | sin datos | 0.017% $ 1.0m | |
| Chief Business Officer | 3.1yrs | sin datos | 0.15% $ 9.4m | |
| Senior Vice President of Manufacturing Operations | 2.6yrs | sin datos | sin datos |
Equipo directivo experimentado: El equipo directivo de LQDA se considera experimentado (3.1 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 5.8yrs | US$7.71m | 2.06% $ 126.3m | |
| Independent Director | 9.9yrs | US$327.50k | 0.046% $ 2.8m | |
| Independent Director | 6.9yrs | US$315.00k | 0.038% $ 2.3m | |
| Independent Chairman | 17.1yrs | US$362.50k | 0.073% $ 4.5m | |
| Independent Director | 5.7yrs | US$305.00k | 5.14% $ 315.5m | |
| Independent Director | 5.3yrs | US$310.00k | 0% $ 0 | |
| Independent Director | 5.7yrs | US$303.62k | 0.097% $ 5.9m | |
| Independent Director | 8.5yrs | US$315.00k | 0.043% $ 2.7m | |
| Independent Director | 6.8yrs | US$312.50k | 0.043% $ 2.7m |
Junta con experiencia: La junta directiva de LQDA se considera experimentada (6.8 años de antigüedad promedio).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/08/24 19:36 |
| Precio de las acciones al final del día | 2026/08/21 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Liquidia Corporation está cubierta por 15 analistas. 7 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Julian Harrison | BTIG |
| Andrew Fein | H.C. Wainwright & Co. |